Replies to post #545432 on NorthWest Biotherapeutics Inc (NWBO)

[SkyLimit2022]

Thoughtful post as usual.

The point is that there are multiple murcidencel clinical trials to consider and each can be researched independently by anyone.

Each study is different—one reached OS, another uses internal placebo, and yet another it testing two other agents in combo. The one noteworthy common feature of all of these studies is the efficacy of murcidencel and the efficacy of certain murcidencel combinations as evidenced by clinical survival data:

The completed P3 is the one completed trial using external controls. Its strongest design feature was the fact that it spanned many years and captured OS data.

https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847


There is another clinical study for rGBM that has reached its midpoint with amazing interim survival data—OS has not been reached yet because patients are alive, but the data would be awesome even if the trial were cut short and ended early. This trial is using an internal placebo control group who are all receiving murcidencel—only Keytruda in combo is being investigated.

https://clinicaltrials.gov/ct2/show/NCT04201873


Furthermore, there is a yet another clinical study to consider …

There’s a trial ongoing since 2010 with 60 patients. It’s at UCLA and uses DCVax + poly ICLC vs. DCVax + Resiquimod vs. placebo. Both are TLR agonists but poly ICLC is showing nearly 50 alive at almost 10 years pic.twitter.com/2ef6bDleuo

— Gregory Zivic, MD (@metacollectiveG) December 6, 2022